Blog

Claim: President Biden recently lauded the Federal Trade Commission’s (FTC) proposal to ban all non-compete agreements — which prevent employees who leave jobs from working for rival firms for a period of time — as a positive step taken to “restore the dignity of work.” He claimed that, under the current agreements, “a cashier at

This year’s star-studded GRAMMY Awards featured extraordinary performances by Stevie Wonder, Smokey Robinson, Missy Elliott, Mary J. Blige, Jay-Z, and more. Their groundbreaking careers and presence on the stage are reminders that the journey to superstardom is not easy. According to the Recording Industry Association of America, it can cost $2 million to break an

Dr. Rachel Goode, an executive at a German generic pharmaceutical company, recently argued that “brand-name drug companies are gaming the [U.S.] patent system” by filing duplicative patents meant to block generics manufacturers from entering the market with cheaper copy-cat treatments. But there’s scant evidence to support that claim. Brand-name drugmakers file patents at a rate

More than two dozen policymakers recently sent a letter to the U.S. Secretary of Health and Human Services, Xavier Becerra, calling on him to misuse a provision of the Bayh-Dole Act to lower the price of the prostate cancer drug Xtandi. The lawmakers’ request, if Becerra grants it, would chill innovation and disincentivize the launch

They may not have green fur or hearts that are three sizes too small. Yet counterfeiters — individuals who illegally reproduce and sell fake versions of a trademarked product — are stealing an unprecedented amount of intellectual property from underneath inventors’ trees this year. As of August, U.S. Customs and Border Protection had confiscated $2.4 billion in

Today, the Office of the U.S. Trade Representative urged the World Trade Organization to postpone making a decision on expanding the TRIPS waiver. Citing the need for more information, USTR plans to ask the U.S. International Trade Commission to investigate the “market dynamics” for Covid-19 diagnostics and therapeutics. But after five months of consultations with

This week, the Senate took a major step toward bolstering America’s innovative ecosystem with the unanimous passage of the Patents for Humanity Act of 2022.  The bipartisan legislation — sponsored by Senators Patrick Leahy (D-VT) and Chuck Grassley (R-IA) — codifies the USPTO’s Patents for Humanity Program, which recognizes U.S. innovators who leverage their patented

The holidays are just around the corner, and many Americans have already started searching for the perfect gifts. And while they may not know it, shoppers have intellectual property protections to thank for almost every product that they’ll put in their carts in the coming weeks. It’s nearly impossible to think of a best-selling kid’s

Chinese President Xi Jinping recently made his strategic priorities abundantly clear as he stacked the highest levels of government with experts in biotechnology, semiconductors, and artificial intelligence. Officials with science and technological expertise now account for almost 40% of the party’s Central Committee — a feat not previously reached in three decades. President Xi’s deliberate promotion of these “technocrats”

A joint WTO communication released by Mexico and Switzerland earlier this month reveals just how senseless a proposed patent waiver for Covid-19 diagnostics and therapeutics is — and just how far the United States has retreated from global leadership on IP. The letter, addressed to the WTO’s TRIPS Council, comes just weeks before a critical

By December 17, the World Trade Organization TRIPS Council is obligated to decide whether to extend the current waiver on Covid-19 vaccines to therapeutics and diagnostics. During recent informal meetings of the Council, South Africa and India remained the most vocal proponents of the expanded waiver. The European Union, the United Kingdom, and the United States have yet to take